50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. (December 2022) - Quixabeira, D.C.A.; Pakola, S.; Jirovec, E.; Basnet, S.; Santos, J.M.; Kudling, T.; Clubb, J.; Haybout, L.; Arias, V.; Grönberg-Vähä-Koskela, S.; Havunen, R.; Cervera-Carrascon, V.; et al.